ad-hcmv-flt3l
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2013 (NCT01811992)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Receptor-type tyrosine-protein kinase FLT3Supplementation
FLT3 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ad-hcmv-flt3l
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06914479 | Phase 1 | Nov 1, 2025 | University of Michigan |
| NCT01811992 | Phase 1 | Dec 1, 2013 | Phase One Foundation, University of Michigan |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Michigan | Academic/Hospital | 2 | 2 | 1 | 2013 |
| Phase One Foundation | Academic/Hospital | 1 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1